CD274 and breast cancer: Recently, immunotherapy options for BC treatments have expanded, with the introduction of the ICI atezolizumab (a PD-L1 antibody) in combination with chemotherapy for the treatment of patients with PD-L1+ unresectable locally advanced or metastatic TNBC (152).